Skip to main content
. 2017 Mar 22;12(3):e0174280. doi: 10.1371/journal.pone.0174280

Fig 3. Overall survival (OS) of the comparison, UFUR <5 months, and UFUR ≥5 months groups.

Fig 3

The 5-year OS rates of the comparison, UFUR <5 months, and UFUR ≥5 months groups were 68.5%, 69.2%, and 90.3%, respectively. UFUR: tegafur-uracil.